|Application ||IHC-P, DB, E|
|Other Accession||Q63802, P47810|
|Calculated MW||71597 Da|
|Other Names||Wee1-like protein kinase, WEE1hu, Wee1A kinase, WEE1|
|Target/Specificity||This Wee1 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S53 of human Wee1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Phospho-Wee1(S53) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. This protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.
Dai, X., et al., J. Invest. Dermatol. 122(6):1356-1364 (2004).
Watanabe, N., et al., Proc. Natl. Acad. Sci. U.S.A. 101(13):4419-4424 (2004).
Yoshida, T., et al., Ann. Oncol. 15(2):252-256 (2004).
Kawasaki, H., et al., Oncogene 22(44):6839-6844 (2003).
Yuan, H., et al., J. Virol. 77(3):2063-2070 (2003).
If you have any additional inquiries please email technical services at email@example.com.